[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Precigen Inc (PGEN)

Precigen Inc (PGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,235,324
  • Shares Outstanding, K 356,511
  • Annual Sales, $ 9,680 K
  • Annual Income, $ -250,640 K
  • EBIT $ -90 M
  • EBITDA $ -85 M
  • 60-Month Beta 1.00
  • Price/Sales 218.68
  • Price/Cash Flow N/A
  • Price/Book 104.65

Options Overview Details

View History
  • Implied Volatility 107.31% (-14.63%)
  • Historical Volatility 67.35%
  • IV Percentile 72%
  • IV Rank 24.84%
  • IV High 256.48% on 08/14/25
  • IV Low 58.01% on 05/15/26
  • Expected Move (DTE 17) 1.19 (18.00%)
  • Put/Call Vol Ratio 0.11
  • Today's Volume 36,465
  • Volume Avg (30-Day) 6,932
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 117,066
  • Open Int (30-Day) 104,198
  • Expected Range 5.42 to 7.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.01
  • Number of Estimates 2
  • High Estimate $-0.01
  • Low Estimate $-0.02
  • Prior Year $-0.11
  • Growth Rate Est. (year over year) +90.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.81 +37.42%
on 07/17/26
6.70 -1.34%
on 08/03/26
+0.97 (+17.20%)
since 07/02/26
3-Month
3.51 +88.32%
on 06/08/26
6.70 -1.34%
on 08/03/26
+2.53 (+62.01%)
since 05/01/26
52-Week
1.70 +288.82%
on 08/11/25
6.70 -1.34%
on 08/03/26
+4.94 (+295.81%)
since 08/01/25

Most Recent Stories

More News
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4

GERMANTOWN, Md. , July 21, 2026 /PRNewswire/ -- Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 6.61 (+5.42%)
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!

In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.

GWRE : 157.33 (+3.55%)
CLDX : 37.69 (-0.97%)
PGEN : 6.61 (+5.42%)
NVO : 47.09 (+0.02%)
AKAM : 117.88 (+2.34%)
SNEX : 76.19 (-0.50%)
ORCL : 141.85 (+9.22%)
ABBV : 245.10 (-2.33%)
GDXJ : 98.67 (+3.44%)
RSP : 217.11 (+0.98%)
VKTX : 32.61 (+2.74%)
LLY : 1,121.36 (-2.39%)
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

GERMANTOWN, Md. and FORT WORTH, Texas , June 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative...

PGEN : 6.61 (+5.42%)
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

GERMANTOWN, Md. , May 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 6.61 (+5.42%)
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

GERMANTOWN, Md. , May 27, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve...

PGEN : 6.61 (+5.42%)
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference

GERMANTOWN, Md. , May 26, 2026 /PRNewswire/ -- Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 6.61 (+5.42%)
Precigen Q1 Earnings Call Highlights

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025.On...

PGEN : 6.61 (+5.42%)
Precigen Reports First Quarter 2026 Financial Results and Business Updates

GERMANTOWN, Md. , May 13, 2026 /PRNewswire/ --  Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 6.61 (+5.42%)
Precigen's First Commercial Quarter Will Test Whether PAPZIMEOS Revenue Can Justify the Pivot

Barchart Research What to Expect from PGEN Earnings PGEN Generated May 12, 2026 Current Price $4.08 EPS Estimate $$-0.03 Consensus Rating Moderate Buy Average Move 9.60% Precigen's First Commercial Quarter...

PGEN : 6.61 (+5.42%)
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

GERMANTOWN, Md. , May 7, 2026 /PRNewswire/ --  Precigen, Inc.  (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines...

PGEN : 6.61 (+5.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional...

See More

Key Turning Points

3rd Resistance Point 7.48
2nd Resistance Point 7.09
1st Resistance Point 6.85
Last Price 6.61
1st Support Level 6.22
2nd Support Level 5.83
3rd Support Level 5.59

See More

52-Week High 6.70
Last Price 6.61
Fibonacci 61.8% 4.79
Fibonacci 50% 4.20
Fibonacci 38.2% 3.61
52-Week Low 1.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.